Clinicaltrials.gov identifier:
NCT04486352 (https://clinicaltrials.gov/show/NCT04486352)
Treatment
This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent endometrial cancer.
Study Contact Information:
For additional information, please contact by phone at (617) 732-8727
or by email at [email protected]
About the Study
This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent endometrial cancer. Participants will be placed into study groups based on their tumor.
What the Study Entails
The study involves 6 groups:
Group 1:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and bevacizumab (Avastin) intravenously every two weeks of the 28-day cycle.
Group 2:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and Ipatasertib orally once daily for 21 days of the 28-day cycle.
Group 3:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and Talazoparib (or Talzenna) orally once daily for every day of the 28-day cycle.
Group 4:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and Trastuzumab emtansine (or Kadcyla) intravenously on Day 1 of each 21-day cycle.
Group 5:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and Tiragolumab intravenously on Day 1 of each 28-day cycle.
Group 6:
Participants will receive Inavolisib and Lentrozole (or Femara) orally once daily for every day of the 28-day cycle.
Study Sites
California
District of Columbia
Florida
Illinois
Massachusetts
Minnesota
Missouri
Nebraska
New Jersey
New York
North Carolina
Oregon
Pennsylvania
Tennessee
Women 18 years or older who:
Patients with:
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.